TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01541917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based coping skills training
Description: This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online disease education
Description: The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse health coach to discuss the participant's efforts at managing his/her disease.
Study: NCT02273570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D
Description: Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
Study: NCT00266695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin
Description: 32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
Study: NCT03793010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006
Description: Single Intra-articular injection
Study: NCT02300155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregvit®
Description: Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orifer F®
Description: Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
Study: NCT04598386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PR Lotion - AMP Human Performance
Description: Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lotion
Description: Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
Study: NCT00396643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids
Description: The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3 fatty acids
Description: The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
Study: NCT01608061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS-f on
Description: deep brain stimulation of the fornix
Study: NCT04234958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Specific protocol including 4 osteopathic techniques targeting the pericardium

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham therapy
Description: Sham therapy mimicking the osteopathic techniques applied to experimental group
Study: NCT03610139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
Study: NCT01428336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1 ug ACTH stimulation test
Description: 1 ug cortrosyn dose
Study: NCT01608061

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS-f off
Description: deep brain stimulation of the fornix turned off
Study: NCT02776137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 20mg/m2/w for 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: a total dose of 60Gy in 30 fractions over 6 weeks
Study: NCT02565212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast,mometazon froat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast,mometazon froat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast,mometazon froat
Study: NCT02508935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XARTEMIS XR
Description: XARTEMIS XR \[7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)\] Extended-Release Tablets
Study: NCT03190031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance respiratory muscle training
Description: Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance inspiratory muscle training
Description: Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance
Study: NCT01707264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEOD001
Description: Monoclonal antibody administered by intravenous infusion every 28 days.
Study: NCT04108026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg IV every 4 weeks
Study: NCT04271865

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Education
Description: Provision of weekly awareness and educational sessions for 6 months. Sessions were conducted at the community based associations within the cases respective villages. Cases were subjected to 24 sessions for improving the patients' own nutrition situation through nutritional education about food rich in iron and counselling. The sessions focused on basic knowledge on iron deficiency anaemia, the most common presenting symptoms, iron rich dietary sources, factors that enhance and inhibit iron absorption, effects of anaemia on health and how to prevent it, Role of dates fruit in preventing and treating anaemia. Th e sessions also focused on the provision of a diverse range of local iron rich food. Special focus was on increasing patients' awareness for self-management of their status

Intervention type: OTHER
Group type: OTHER
Intervention: model nutrition kitchen
Description: Implementing model nutrition kitchen; once every month for six months with six sessions for each village (6 sessions/village) with cooking sessions was done to promote eating healthy and provide innovative ideas for feeding anaemic cases. 117 patients were reached by the nutritional kitchen activities with 6 sessions until the end of the project. Special focus was done on skills like sharing cooking, meal planning, and label reading that help support healthy eating patterns. Suggesting ways that individuals can model healthy eating behaviors for friends and family members that is based on Dates fruit was encouraged.

Intervention type: OTHER
Group type: OTHER
Intervention: recipe book
Description: 3) Development of recipe book that is based on the local food in the market to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
Study: NCT00987779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
Study: NCT04583189

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Performance of the test antigenic and test RT-PCR
Description: Each patient will have 1 test rapid antigenic Biosynex Covid-19 Ag-BSS with the results in 15-20 minutes and 1 reference test RT-PCR analyzed in microbiology laboratory of the hospital.
Study: NCT02803658

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking behavior

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking behavior

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sperm collection
Study: NCT01165528

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: type of mechanical ventilation
Description: patients are randomized to receive one of the two types of mechanical ventilation for ARDS
Study: NCT01428336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1 ug ACTH stimulation test
Description: 1 ug cortrosyn dose

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 250 ug ACTH stimulation test
Description: ACTH stimulation test will be done using 250 ug cortrosyn dose
Study: NCT02315274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frequent remote contact between clinic visits.
Description: Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
Study: NCT03523299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation is a non-surgical, minimally invasive freezing procedure used to destroy tumors. In the breast, cryoablation is performed under ultrasound guidance. Due to the analgesic properties of freezing, no IV sedation or anesthesia is required. After administration of local anesthetic, the physician makes a 2-3 mm incision and inserts needle-like cryoprobes into the tumor, commencing a number of freeze-thaw cycles. Then the probe is removed, pressure is applied to the area, and a bandage is placed. The patient leaves the office without stitches and minimal, if any, pain. Any residual pain after the procedure is routinely treated with over the counter analgesics such as acetaminophen.
Study: NCT00456300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Each subject received a baseline study with insulin alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Each subject received a baseline study with insulin alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Each subject received a baseline study with insulin alone
Study: NCT00727597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz 600mg
Description: QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boosted Lexiva
Description: Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)
Study: NCT01905436

Intervention type: DRUG
Intervention: Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
Description: Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.

Intervention type: DRUG
Intervention: Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
Description: Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
Study: NCT00373633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural
Description: Gold standard for post thoracotomy pain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extrapleural Intercostal Catheter
Description: Continuous extra-pleural intercostal local anesthesia
Study: NCT02489344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ/SAR402671
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT00798044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other: quality improvement feedback system
Description: Surveys patients regarding treatment experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Feedback
Description: Weekly feedback reports provided to counselors
Study: NCT00366158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: St. Jude Medical Victory dual-chamber pacemaker
Description: Pacemaker implant
Study: NCT03438292

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
Study: NCT01428336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 250 ug ACTH stimulation test
Description: ACTH stimulation test will be done using 250 ug cortrosyn dose

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25 ug Cortrosyn stimulation test
Description: ACTH stimulation test using a 25 ug cortrosyn dose
Study: NCT04271865

Intervention type: OTHER
Group type: OTHER
Intervention: Provision of Dates
Description: Dates fruit intake for all the anaemic patients was provided for 16 weeks (four months):~• Diagnosed anemic patients were given five to seven pieces of Dates (dependent on its weight) on daily basis for 16 weeks (each date fruits is about 10 -20 gm). Dates was taken as breakfast on daily base.~The Dates fruit that was used during the proposed trial is Saudi's Dates extract know as Barni which is organic Dates. The fruit is mentioned more than 20 times in the Quran, This Barni is known for its very high nutritive value (vitamins, minerals and antioxidants) compared with other Dates types. The nutritive value of Barni is shown in the below table, calculated per every 100 gram (range 5- 10 pieces) of dry weight (DW) :~The nutritive value of Barni calculated per every 100 gram (average 7-10 pieces) of dry weight (DW) of which iron constitutes 6.78 mg that represent 67.8 % of the recommended dietary allowance (RDA) of the males and 45.20 % of the RDA of the females
Study: NCT01428336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25 ug Cortrosyn stimulation test
Description: ACTH stimulation test using a 25 ug cortrosyn dose

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin tolerance test
Description: subjects will undergo an insulin tolerance test

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin tolerance test
Description: subjects will undergo an insulin tolerance test
Study: NCT02230371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo)
Description: If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
Study: NCT00620152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1
Description: Low glycemic load diet by telephone counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2
Description: Low fat diet by telephone counseling
Study: NCT01855152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimised WHELD intervention
Description: Experimental: Optimised WHELD intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment delivered as usual in the care home
Study: NCT02317952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Extensively Hydrolyzed Formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Formula
Study: NCT01519739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediGuide™
Description: MediGuide™ system will be used to guide CRT implants
Study: NCT00366158

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: St. Jude Medical Victory dual-chamber pacemaker
Description: Pacemaker implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventricular Intrinsic Preference
Description: Programming of pacemaker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular Intrinsic Preference
Description: Programming of pacemaker
Study: NCT03679780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-788
Description: This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
Study: NCT03793010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single Intra-articular injection
Study: NCT02660073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES+FES
Description: 12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control+FES
Description: 12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
Study: NCT02616328

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study: NCT00939146

Intervention type: OTHER
Group type: OTHER
Intervention: Outlook Attention Control
Description: Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.

Intervention type: OTHER
Group type: OTHER
Intervention: Outlook Intervention
Description: The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.